Treatment Resistant Depression

On May 1, new partners Canadian psychedelics developer PharmAla Biotech and Australian digital healthcare business Vitura Health (formerly Cronos Australia) announced the definitive establishment of a 50-50 joint venture Cortexa.  On May 20, the CEOs of both PharmAla and Vitura hosted a...

Clinical-stage psychedelics biotech atai Life Sciences (NASDAQ: ATAI) shared the results of its NYC-based subsidiary NYC-based Perception Neuroscience’s Phase 2a study of proprietary R-ketamine PCN-101 on patients with Treatment-Resistant Depression (TRD.). The company stated that while the...

What a year for psychedelics! It feels like we’ve come a long way since the sector explode in 2019-2020, the launch of Benzinga's Psyched, companies’ massive migration from private to public, MAPS’ initiation of Phase 3 MDMA trials, the surge of the psilocybin wave,...

Private clinical-stage psychedelics biotech Beckley Psytech Ltd. has initiated a Phase 2a proof-of-concept study on BPL-003, its proprietary intranasal formulation of synthetic 5-MeO-DMT for Treatment-Resistant Depression (TRD.) Founded in 2019 and yet based on more than two decades of...

Psychedelics biotech company Biomind Labs Inc. (OTC: BMNDF) has announced positive initial results from part 1 of a Phase 2 clinical trial on its proprietary liquid inhaled formulation of DMT, BMND01, designed for Treatment-Resistant Depression (TRD). Through its R&D acceleration platform,...

Clinical stage psychedelics company atai Life Sciences (NASDAQ: ATAI) and its majority-owned subsidiary Perception Neuroscience completed patient enrollment for their Phase 2a clinical trial assessing the safety and efficacy of a single intravenous infusion (IV) dose of proprietary R-...

GH Research PLC (NASDAQ: GHRS), the clinical-stage biopharma company dedicated to transforming the treatment of psychiatric and neurological disorders through 5-MeO-DMT production, provided a financial and business update for the quarter ended June 30, 2022. The financial results for the...

Clinical-stage psychedelics company ATAI Life Sciences N.V. (NASDAQ: ATAI) announced its financial results for the quarter ended June 30, 2022 and business updates, including a term loan facility agreement for up to $175 million provided by Hercules Capital Inc. (NYSE: HTGC). The company...